Application No.: 10/040281 Docket No.: BGNB129CP2DV2CN

## **Amendments to the Claims**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

## **Listing of Claims**

f

## Claims 1-32. Canceled.

- 33. (Presently Amended) A method for treating or lessening the advancement, severity, or effects of an autoimmune disease neoplasia, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide complex comprising a first polypeptide selected from a group consisting of
  - (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
  - (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
  - (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;
- (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2 wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue; and

a second polypeptide which is lymphotoxin- $\alpha$ .

## Claims 34-38. Canceled.

- 39. (New) The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2.
- 40. (New) The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4.
- 41. (New) The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6.
- 42. (New) The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2, wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.